Opendata, web and dolomites

BERMES SIGNED

A Novel BERberine derivative for Malignant MESothelioma

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BERMES project word cloud

Explore the words cloud of the BERMES project. It provides you a very rough idea of what is the project "BERMES" about.

nax035    close    pulling    covers    diagnosis    rare    peak    cavity    banned    gap    good    bermes    organization    period    trial    therapy    clinical    resistant    valley    january    testis    translational    lungs    agency    first    survival    medicine    shown    44    data    death    arising    internal    exhibited    drug    oral    2005    2020    malignant    burden    obtaining    organs    agent    deal    trials    despite    innovative    health    right    undertaken    treatment    designation    limited    emergence    derivative    drugs    mm    union    cisplatin    pharmacokinetic    orphan    mesothelium    last    disease    completion    aggressive    thin    pemetrexed    malignancy    definitely    solved    worldwide    manufacture    antitumour    regulatory    mesothelioma    improvement    chemoresistance    peritoneal    tissue    incidences    none    combination    toxicity    latency    heart    efficacy    exposure    layer    safety    line    world    authorization    preliminary    administered    berberine    asbestos    forms    standard   

Project "BERMES" data sheet

The following table provides information about the project.

Coordinator
APPLIED RESEARCH USING OMIC SCIENCES SL 

Organization address
address: CALLE VICTOR PRADERA 45
city: CORNELLA
postcode: 8940
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 1˙550˙942 €
 EC max contribution 1˙085˙659 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-11-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    APPLIED RESEARCH USING OMIC SCIENCES SL ES (CORNELLA) coordinator 1˙085˙659.00

Map

 Project objective

Malignant Mesothelioma (MM) is a rare, aggressive and highly treatment-resistant malignancy arising in the thin layer of tissue known as mesothelium, which covers many of the important internal organs like the lungs, the peritoneal cavity, the heart and the testis. The World Health Organization has recognized that all forms of mesothelioma are strongly associated with asbestos exposure and that its burden is increasing worldwide. Asbestos was definitely banned in European Union in January 2005. However, since the disease has a long latency period (44.6 years from exposure to diagnosis), peak incidences are expected in EU beyond 2020. The standard first line treatment is the combination of pemetrexed and cisplatin with limited efficacy and side-effects. Despite a great deal of research has been undertaken during the last 10 years, none of the current drugs under clinical trials has shown yet an improvement in overall survival over existing standard therapy or solved the emergence of chemoresistance. NAX035, an innovative berberine derivative has exhibited efficacy as antitumour agent with a good preliminary pharmacokinetic, toxicity and safety data when administered as oral therapy for the treatment of malignant mesothelioma. Activities of BERMES (BERberine derivative for MESothelioma treatment are expected to close the translational gap (death valley) by pulling the product up to the clinical development: BERMES will focus on completion of the non-clinical package and the drug manufacture with the aim of obtaining the orphan drug designation as well as to accomplish all the regulatory requirements required by the European Medicine Agency to achieve the clinical trial authorization to proceed into clinical trial right after the end of the project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BERMES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BERMES" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

STURSKIN (2018)

Innovative products by using tanned sturgeon skin

Read More  

ALR4000 (2019)

Automated LCD Recycling series 4000

Read More